Handbook of experimental pharmacology最新文献_第9页

Structure and Function of Calcium-Activated Chloride Channels and Phospholipid Scramblases in the TMEM16 Family. TMEM16 家族中钙激活氯离子通道和磷脂搓揉酶的结构与功能

Handbook of experimental pharmacology Pub Date : 2024-01-01 DOI: 10.1007/164_2022_595

Dung Manh Nguyen, Tsung-Yu Chen

引用次数: 0

Characterization of Drug Delivery Systems by Transmission Electron Microscopy. 用透射电子显微镜表征药物传递系统。

Handbook of experimental pharmacology Pub Date : 2024-01-01 DOI: 10.1007/164_2023_699

Stephanie Hoeppener

引用次数: 0

Life Science Incubation at LabCentral/BioLabs with Partners Extending from the USA to Europe. 在 LabCentral/BioLabs 进行生命科学孵化，合作伙伴从美国扩展到欧洲。

Handbook of experimental pharmacology Pub Date : 2024-01-01 DOI: 10.1007/164_2024_727

Johannes Fruehauf

引用次数: 0

The Alliance Between the German Cancer Research Center and Bayer: A Retrospective of an Innovative Collaboration Model. 德国癌症研究中心与拜耳的联盟：创新合作模式回顾。

Handbook of experimental pharmacology Pub Date : 2024-01-01 DOI: 10.1007/164_2024_726

A Zuccotti, R Carretero, H Hess-Stumpp

{"title":"The Alliance Between the German Cancer Research Center and Bayer: A Retrospective of an Innovative Collaboration Model.","authors":"A Zuccotti, R Carretero, H Hess-Stumpp","doi":"10.1007/164_2024_726","DOIUrl":"10.1007/164_2024_726","url":null,"abstract":"In 2009, the German Cancer Research Center (DKFZ) and the biopharmaceutical company Bayer AG initiated an academic-industry co-discovery collaboration. The partners combined their expertise in tumor biology and drug discovery to identify and validate novel targets for cancer treatment. In the early phase of the Alliance, the focus was on target identification and validation projects. Over time, both partners realized that they could also successfully collaborate on later stages of drug discovery. As a result over the past few years, and following several contract extensions, the two partners have collaborated on several late-stage drug discovery projects. This has resulted in the achievement of several drug discovery milestones and the initiation of early clinical trials, the most recent in 2022. This success has been possible thanks to both partners' understanding of each other's needs and challenges. They jointly developed solutions to issues such as the intrinsic potential conflict of early publishing versus patent protection. Both partners also appreciated the risks involved in some of the experiments, such as starting a joint laboratory for immune-therapy with scientists from both parties working bench-to-bench. Recently, despite these successes the partners decided to terminate the Alliance, as Bayer AG wants to focus its activities on the development of its late pipeline.","PeriodicalId":12859,"journal":{"name":"Handbook of experimental pharmacology","volume":" ","pages":"83-95"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142035698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Natural Products Drug Discovery: On Silica or In-Silico? 天然产物药物发现:二氧化硅还是硅基?

Handbook of experimental pharmacology Pub Date : 2023-01-01 DOI: 10.1007/164_2022_611

Hye Kyong Kim, Young Hae Choi, Robert Verpoorte

{"title":"Natural Products Drug Discovery: On Silica or In-Silico?","authors":"Hye Kyong Kim, Young Hae Choi, Robert Verpoorte","doi":"10.1007/164_2022_611","DOIUrl":"https://doi.org/10.1007/164_2022_611","url":null,"abstract":"Natural products have been the most important source for drug development throughout the human history. Over time, the formulation of drugs has evolved from crude drugs to refined chemicals. In modern drug discovery, conventional natural products lead-finding usually uses a top-down approach, namely bio-guided fractionation. In this approach, the crude extracts are separated by chromatography and resulting fractions are tested for activity. Subsequently, active fractions are further refined until a single active compound is obtained. However, this is a painstakingly slow and expensive process. Among the alternatives that have been developed to improve this situation, metabolomics has proved to yield interesting results having been applied successfully to drug discovery in the last two decades. The metabolomics-based approach in lead-finding comprises two steps: (1) in-depth chemical profiling of target samples, e.g. plant extracts, and bioactivity assessment, (2) correlation of the chemical and biological data by chemometrics. In the first step of this approach, the target samples are chemically profiled in an untargeted manner to detect as many compounds as possible. So far, NMR spectroscopy, LC-MS, GC-MS, and MS/MS spectrometry are the most common profiling tools. The profile data are correlated with the biological activity with the help of various chemometric methods such as multivariate data analysis. This in-silico analysis has a high potential to replace or complement conventional on-silica bioassay-guided fractionation as it will greatly reduce the number of bioassays, and thus time and costs. Moreover, it may reveal synergistic mechanisms, when present, something for which the classical top-down approach is clearly not suited. This chapter aims to give an overview of successful approaches based on the application of chemical profiling with chemometrics in natural products drug discovery.","PeriodicalId":12859,"journal":{"name":"Handbook of experimental pharmacology","volume":"277 ","pages":"117-141"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9095787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Harnessing Human Pluripotent Stem Cell-Derived Pancreatic In Vitro Models for High-Throughput Toxicity Testing and Diabetes Drug Discovery. 利用人类多能干细胞衍生的胰腺体外模型进行高通量毒性测试和糖尿病药物发现。

Handbook of experimental pharmacology Pub Date : 2023-01-01 DOI: 10.1007/164_2023_655

Carmen Ching, Elhadi Iich, Adrian Kee Keong Teo

{"title":"Harnessing Human Pluripotent Stem Cell-Derived Pancreatic In Vitro Models for High-Throughput Toxicity Testing and Diabetes Drug Discovery.","authors":"Carmen Ching, Elhadi Iich, Adrian Kee Keong Teo","doi":"10.1007/164_2023_655","DOIUrl":"10.1007/164_2023_655","url":null,"abstract":"The long-standing goals in diabetes research are to improve β-cell survival, functionality and increase β-cell mass. Current strategies to manage diabetes progression are still not ideal for sustained maintenance of normoglycemia, thereby increasing demand for the development of novel drugs. Available pancreatic cell lines, cadaveric islets, and their culture methods and formats, either 2D or 3D, allow for multiple avenues of experimental design to address diverse aims in the research setting. More specifically, these pancreatic cells have been employed in toxicity testing, diabetes drug screens, and with careful curation, can be optimized for use in efficient high-throughput screenings (HTS). This has since spearheaded the understanding of disease progression and related mechanisms, as well as the discovery of potential drug candidates which could be the cornerstone for diabetes treatment. This book chapter will touch on the pros and cons of the most widely used pancreatic cells, including the more recent human pluripotent stem cell-derived pancreatic cells, and HTS strategies (cell models, design, readouts) that can be used for the purpose of toxicity testing and diabetes drug discovery.","PeriodicalId":12859,"journal":{"name":"Handbook of experimental pharmacology","volume":" ","pages":"301-332"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9613854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biological and Clinical Implications of Sex-Specific Differences in Alzheimer's Disease. 阿尔茨海默病性别特异性差异的生物学和临床意义。

Handbook of experimental pharmacology Pub Date : 2023-01-01 DOI: 10.1007/164_2023_672

Jose A Santiago, Judith A Potashkin

引用次数: 0

Sex-Gender-Based Differences in Metabolic Diseases. 代谢性疾病中基于性别的差异。

Handbook of experimental pharmacology Pub Date : 2023-01-01 DOI: 10.1007/164_2023_683

Ilaria Campesi, Margherita Ruoppolo, Flavia Franconi, Marianna Caterino, Michele Costanzo

{"title":"Sex-Gender-Based Differences in Metabolic Diseases.","authors":"Ilaria Campesi, Margherita Ruoppolo, Flavia Franconi, Marianna Caterino, Michele Costanzo","doi":"10.1007/164_2023_683","DOIUrl":"10.1007/164_2023_683","url":null,"abstract":"Sexual dimorphism creates different biological and cellular activities and selective regulation mechanisms in males and females, thus generating differential responses in health and disease. In this scenario, the sex itself is a source of physiologic metabolic disparities that depend on constitutive genetic and epigenetic features that characterize in a specific manner one sex or the other. This has as a direct consequence a huge impact on the metabolic routes that drive the phenotype of an individual. The impact of sex is being clearly recognized also in disease, whereas male and females are more prone to the development of some disorders, or have selective responses to drugs and therapeutic treatments. Actually, very less is known regarding the probable differences guided by sex in the context of inherited metabolic disorders, owing to the scarce consideration of sex in such restricted field, accompanied by an intrinsic bias connected with the rarity of such diseases. Metabolomics technologies have been ultimately developed and adopted for being excellent tools for the investigation of metabolic mechanisms, for marker discovery or monitoring, and for supporting diagnostic procedures of metabolic disorders. Hence, metabolomic approaches can excellently embrace the discovery of sex differences, especially when associated to the outcome or the management of certain inborn errors of the metabolism.","PeriodicalId":12859,"journal":{"name":"Handbook of experimental pharmacology","volume":" ","pages":"241-257"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9974722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sex Differences in Pharmacokinetics. 药物动力学中的性别差异。

Handbook of experimental pharmacology Pub Date : 2023-01-01 DOI: 10.1007/164_2023_669

Irving Zucker, Brian J Prendergast

引用次数: 9

Ca_V3.2 (CACNA1H) in Primary Aldosteronism. 原发性醛固酮增多症的CaV3.2 (CACNA1H)。

Handbook of experimental pharmacology Pub Date : 2023-01-01 DOI: 10.1007/164_2023_660

Hoang An Dinh, Gabriel Stölting, Ute I Scholl

引用次数: 0